中國抗體-B(03681.HK)總裁強靜向致譽投資購買4133萬股公司股份
格隆匯5月26日丨中國抗體-B(03681.HK)公佈,公司董事會獲通知,於2020年5月26日,致譽投資集團有限公司(作為賣方,為公司的控股股東之一)已與格擎生物科技有限公司(格擎生物,作為買方)及其他方訂立買賣協議,格擎生物同意購買公司4133萬股股份,價格為每股銷售股份3.50港元。銷售股份佔公司已發行股本總額約4.11%。格擎生物由公司執行董事兼總裁強靜先生全資擁有,強先生為公司非執行董事劉文溢女士的配偶。
完成買賣協議後,致譽投資將被視為擁有公司3.48億股股份(佔公司已發行股本總額約34.60%),強先生及劉女士各自將被視為擁有公司2.54億股股份(佔公司已發行股本總額約25.27%),而致譽投資及其他一致行動人士各自將仍為公司的控股股東。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.